Home/ Stocks/ ANTX

AN2 Therapeutics, Inc. Common Stock

ANTX XNAS

$5.93 -0.15 (-2.47%) ▼ 15-min delayed

Open

$6.12

High

$6.17

Low

$5.78

Volume

124.5K

Market Cap

$218.98M

About AN2 Therapeutics, Inc. Common Stock

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 21 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-10,028,000	$-0.29
Q3 2025	$0	$-9,353,000	$-0.31
Q2 2025	$0	$-6,462,000	$-0.21
Q1 2025	$0	$-10,649,000	$-0.35

Related Market News

No specific coverage for ANTX yet. Check out our latest market news or earnings calendar.

Get ANTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on AN2 Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.